Compare FN & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FN | DGX |
|---|---|---|
| Founded | 1999 | 1967 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3B | 21.0B |
| IPO Year | 2007 | 1996 |
| Metric | FN | DGX |
|---|---|---|
| Price | $621.25 | $200.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 13 |
| Target Price | ★ $513.43 | $214.38 |
| AVG Volume (30 Days) | ★ 824.9K | 623.9K |
| Earning Date | 05-04-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 1.82% |
| EPS Growth | 13.21 | ★ 13.78 |
| EPS | ★ 9.22 | 2.24 |
| Revenue | $3,419,327,000.00 | ★ $11,035,000,000.00 |
| Revenue This Year | $36.87 | $7.53 |
| Revenue Next Year | $17.91 | $3.77 |
| P/E Ratio | ★ $77.99 | $87.54 |
| Revenue Growth | ★ 18.60 | 11.78 |
| 52 Week Low | $231.51 | $164.65 |
| 52 Week High | $748.89 | $213.50 |
| Indicator | FN | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 44.63 | 63.13 |
| Support Level | $615.03 | $194.09 |
| Resistance Level | $631.95 | $212.16 |
| Average True Range (ATR) | 51.46 | 3.82 |
| MACD | -3.79 | 0.83 |
| Stochastic Oscillator | 13.81 | 90.02 |
Fabrinet provides advance-level optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of complex products, such as optical communication components, modules and sub-systems, industrial lasers, automotive components, medical devices, and sensors. The company offers a broad range of advance optical and electro-mechanical capabilities across the entire manufacturing process, including process design and engineering, supply chain management, manufacturing, complex printed circuit board assembly, advance-level of packaging, integration, final assembly, and testing. The company generates the majority of its revenue from North America and Asia-Pacific, with the rest from Europe.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.